Phase 2 study to compare INBRX-101 to plasma derived A1PI therapy in adults with AATD emphysema
- Investigator
- Jorge E Lascano
- Status
- Accepting Candidates
- Ages
- 18 Years - 80 Years
- Sexes
- All
Update your location to show providers, locations, and services closest to you.
Critical Care Specialist
Phase 2 study to compare INBRX-101 to plasma derived A1PI therapy in adults with AATD emphysema
The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 180 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in…
41 publications
2023
Chronic obstructive pulmonary diseases (Miami, Fla.)
PubMed • Publisher's site2023
ERJ open research
PubMed • Publisher's site2023
Annals of the American Thoracic Society
PubMed • Publisher's site2023
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
PubMed • Publisher's site2023
Respiratory research
PubMed • Publisher's site